[Federal Register Volume 81, Number 72 (Thursday, April 14, 2016)]
[Notices]
[Pages 22119-22120]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-08574]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Medical Technology Enterprise Consortium
Notice is hereby given that, on March 15, 2016, pursuant to Section
6(a) of the National Cooperative Research and
[[Page 22120]]
Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''), the
Medical Technology Enterprise Consortium (``MTEC'') has filed written
notifications simultaneously with the Attorney General and the Federal
Trade Commission disclosing changes in its membership and nature and
objectives. The notifications were filed for the purpose of extending
the Act's provisions limiting the recovery of antitrust plaintiffs to
actual damages under specified circumstances. Specifically, Agile
Immersive, Arlington, VA; Armed Forces Institute for Regenerative
Medicine (AFIRM), Winston-Salem, NC; Articulate Biomedical, LLC,
Ithaca, NY; BioMed SA, San Antonio, TX; Cedars-Sinai Medical Center,
Los Angeles, CA; CUBRC, Inc., Buffalo, NY; Eagle Applied Sciences, LLC,
San Antonio, TX; East Carolina University, Greenville, NC; FirstString
Research, Inc., Mt. Pleasant, SC; Gateway Biotechnology, Inc., Kent,
OH; General Electric Company, Global Research, Niskayuna, NY; Georgia
Tech Research Corporation, Atlanta, GA; IDIQ, Inc., Fallbrook, CA;
InnoVital Systems, Inc., Beltsville, MD; Johns Hopkins University,
Baltimore, MD; and Kestrel Corporation, Albuquerque, NM, Lovelace
Biomedical and Environmental Research Institute, Albuquerque, NM;
McAllister & Quinn, LLC, Washington, DC; Medical University of South
Carolina, Charleston, SC; MedPro Technologies, Inc., San Antonio, TX;
Michigan Technological University, Houghton, MI; MicroCures, Inc.,
Santa Cruz, CA; MiMedx Group, Inc., Marietta, GA; New York Institute of
Technology, Old Westbury, NY; North American Rescue, LLC, Greer, SC;
Otologic Pharmaceutics, Inc., Oklahoma City, OK; Pertexa Healthcare
Technologies, Inc., Ridgecrest, CA; Qool Therapeutics, Inc., Menlo
Park, CA; RegenMed Development Organization, Winston-Salem, NC;
Resiliency Technologies, Inc., Spartanburg, SC; Second Sight Medical
Products, Inc., Sylmar, CA; Southwest Research Institute, San Antonio,
TX; Techline Technologies, Inc., Willow Grove, PA; The Conafay Group,
Washington, DC; The General Hospital Corporation dba Massachusetts
General Hospital, Boston, MA; The Henry M. Jackson Foundation for the
Advancement of Military Medicine, Bethesda, MD; The Ohio State
University, Columbus, OH; The Research Foundation for the State
University of New York (SUNY), Syracuse, NY; The University of Texas at
Arlington Research Institute (UTARI), Arlington, TX; Trideum
Biosciences, Frederick, MD; Triton Systems, Inc., Chelmsford, MA;
University of Illinois at Chicago, Chicago, IL; University of Miami,
Coral Gables, FL; University of Michigan, Ann Arbor, MI; University of
Nebraska Medical Center, Omaha, NE; University of Pittsburgh,
Pittsburgh, PA; University of South Carolina, Columbia, SC; University
of Virginia, Charlottesville, VA; Vanderbilt University School of
Engineering, Nashville, TN; Wake Forest University Health Sciences,
Winston-Salem, NC; and Weinberg Medical Physics, LLC, North Bethesda,
MD, have been added as parties to this venture.
Also, Biohealth Innovation, Inc., Rockville, MD; Center for
Integration of Medicine and Innovative Technology (CIMIT), Boston, MA;
Florida Atlantic University, Boca Raton, FL; Indiana University,
Bloomington, IN; Institute for Systems Biology, Seattle, WA; Jade
Therapeutics, Inc., Salt Lake City, UT; Johns Hopkins Technology
Transfer, Baltimore, MD; KAI Research, Inc. (KAI), Rockville, MD; Human
Effects Modeling, Advanced Technology, Inc., L-3 Communications, San
Diego, CA; Maryland Technology Development Corp. (TEDCO), Columbia, MD;
and Institute for Collaborative Biotechnologies, University of
California, Santa Barbara, CA, have withdrawn as parties to this
venture.
The general areas of MTEC's planned activity are to: (a) enter into
an Other Transactions Agreement with the U.S. Army Medical Research and
Materiel Command (the Government) to fund certain research,
development, and commercialization efforts conducted in partnership
with the Government, the Consortium, and Consortium Members that
enhance the medical knowledge and life cycle management of the medical
program, and enable the Government to better protect, treat, and
optimize Warfighter health and performance across the full spectrum of
operations; (b) participate in establishing sound technical and
programmatic performance goals based on the needs and requirements of
the Government's Technology Objectives and other mission requirements;
(c) create programs and secure funding; (d) provide a unified voice
that effectively articulates the strategically important role military
medical technologies play in current and future military operations;
and (e) maximize use of Government and member capabilities and
resources for developing critical processes, procedures, drugs,
vaccines, and devices that can be transitioned and commercialized for
both military and civilian use.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and MTEC intends to file additional
written notifications disclosing all changes in membership.
On May 9, 2014, MTEC filed its original notification pursuant to
Section 6(a) of the Act. The Department of Justice published a notice
in the Federal Register pursuant to Section 6(b) of the Act on June 9,
2014 (79 FR 32999).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2016-08574 Filed 4-13-16; 8:45 am]
BILLING CODE P